Literature DB >> 18034212

Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report.

Walter Stummer1, Tobias Beck, Wolfgang Beyer, Jan Hendrik Mehrkens, Andreas Obermeier, Nima Etminan, Herbert Stepp, Jörg-Christian Tonn, Reinhold Baumgartner, Jochen Herms, Friedrich Wilhelm Kreth.   

Abstract

Glioblastoma multiforme continues to be a devastating disease despite modest improvements in survival achieved at present, and there is an urgent need for innovative treatment concepts. Five-aminolevulinic acid (ALA) is a drug which induces protoporphyrin IX accumulation in malignant gliomas and has been explored for fluorescence-guided resections of these tumors. ALA is also under investigation as a photosensitizer. We report a case of a patient with prior left frontal glioblastoma multiforme treated by surgery, radiation and chemotherapy, who developed a remote lesion in the left insula, which was refractory to secondary treatments. In a compassionate use setting she was treated by oral application of ALA (20 mg/kg bodyweight), and stereotactic phototherapy achieved by positioning four laser diffusors using 3-dimensional irradiation planning, and a 633 nm diode laser. The lesion disappeared 24 h after therapy. Circumferential contrast enhancement was observed at 72 h, which disappeared in the course of subsequent months. Edema resolved completely. The patient is still free of recurrence 56 months after treatment, demonstrating an impressive and long-lasting response to this novel mode of therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18034212     DOI: 10.1007/s11060-007-9497-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  29 in total

Review 1.  Photodynamic therapy and detection of high-grade gliomas.

Authors:  Steen Madsen; Henry Hirschberg
Journal:  J Environ Pathol Toxicol Oncol       Date:  2006       Impact factor: 3.567

2.  In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid.

Authors:  W Stummer; S Stocker; A Novotny; A Heimann; O Sauer; O Kempski; N Plesnila; J Wietzorrek; H J Reulen
Journal:  J Photochem Photobiol B       Date:  1998-09       Impact factor: 6.252

3.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

4.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

5.  Acute morphological sequelae of photodynamic therapy with 5-aminolevulinic acid in the C6 spheroid model.

Authors:  Pitr Zelenkov; Reinhold Baumgartner; Karl Bise; Michael Heide; Richard Meier; Susanne Stocker; Ronald Sroka; Roland Goldbrunner; Walter Stummer
Journal:  J Neurooncol       Date:  2006-09-27       Impact factor: 4.130

6.  Damage to tumour and brain by interstitial photodynamic therapy in the 9L rat tumour model comparing intravenous and intratumoral administration of the photosensitiser.

Authors:  K M Hebeda; W Kamphorst; H J Sterenborg; J G Wolbers
Journal:  Acta Neurochir (Wien)       Date:  1998       Impact factor: 2.216

7.  Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors.

Authors:  Meic H Schmidt; Glenn A Meyer; Kenneth W Reichert; Joseph Cheng; Hendrikus G Krouwer; Kutlan Ozker; Harry T Whelan
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

8.  Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX.

Authors:  Tobias J Beck; Friedrich W Kreth; Wolfgang Beyer; Jan H Mehrkens; Andreas Obermeier; Herbert Stepp; Walter Stummer; Reinhold Baumgartner
Journal:  Lasers Surg Med       Date:  2007-06       Impact factor: 4.025

9.  The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model.

Authors:  H T Whelan; M H Schmidt; A D Segura; T L McAuliffe; D M Bajic; K J Murray; J E Moulder; D R Strother; J P Thomas; G A Meyer
Journal:  J Neurosurg       Date:  1993-10       Impact factor: 5.115

10.  Stereotactic intratumoral photodynamic therapy for recurrent malignant brain tumors.

Authors:  S K Powers; S S Cush; D L Walstad; L Kwock
Journal:  Neurosurgery       Date:  1991-11       Impact factor: 4.654

View more
  23 in total

1.  Three-dimensional skeletonization and symbolic description in vascular imaging: preliminary results.

Authors:  L Verscheure; L Peyrodie; A S Dewalle; N Reyns; N Betrouni; S Mordon; M Vermandel
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-07-31       Impact factor: 2.924

Review 2.  Optical technologies for intraoperative neurosurgical guidance.

Authors:  Pablo A Valdés; David W Roberts; Fa-Ke Lu; Alexandra Golby
Journal:  Neurosurg Focus       Date:  2016-03       Impact factor: 4.047

3.  Successful in vivo tumor visualization using fluorescence laparoscopy in a mouse model of disseminated alveolar rhabdomyosarcoma.

Authors:  Cristian Urla; Sorin Armeanu-Ebinger; Jörg Fuchs; Guido Seitz
Journal:  Surg Endosc       Date:  2014-08-23       Impact factor: 4.584

4.  Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI.

Authors:  Norbert Galldiks; Marion Rapp; Gabriele Stoffels; Gereon R Fink; Nadim J Shah; Heinz H Coenen; Michael Sabel; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-29       Impact factor: 9.236

Review 5.  Vitamin D and Other Differentiation-promoting Agents as Neoadjuvants for Photodynamic Therapy of Cancer.

Authors:  Edward V Maytin; Tayyaba Hasan
Journal:  Photochem Photobiol       Date:  2020-04-15       Impact factor: 3.421

6.  Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening.

Authors:  Costas G Hadjipanayis; Huabei Jiang; David W Roberts; Lily Yang
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 7.  Emerging Applications of Therapeutic Ultrasound in Neuro-oncology: Moving Beyond Tumor Ablation.

Authors:  David S Hersh; Anthony J Kim; Jeffrey A Winkles; Howard M Eisenberg; Graeme F Woodworth; Victor Frenkel
Journal:  Neurosurgery       Date:  2016-11       Impact factor: 4.654

Review 8.  Neurosurgery for brain tumors: update on recent technical advances.

Authors:  Jonathan H Sherman; Kathryn Hoes; Joshua Marcus; Ricardo J Komotar; Cameron W Brennan; Philip H Gutin
Journal:  Curr Neurol Neurosci Rep       Date:  2011-06       Impact factor: 5.081

9.  The use of 5-aminolevulinic acid in resection of pediatric brain tumors: a critical review.

Authors:  Chenran Zhang; Frederick A Boop; John Ruge
Journal:  J Neurooncol       Date:  2018-11-15       Impact factor: 4.130

10.  Dexamethasone alone and in combination with desipramine, phenytoin, valproic acid or levetiracetam interferes with 5-ALA-mediated PpIX production and cellular retention in glioblastoma cells.

Authors:  Johnathan E Lawrence; Christopher J Steele; Richard A Rovin; Robert J Belton; Robert J Winn
Journal:  J Neurooncol       Date:  2015-12-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.